UK: Parallel Importation Of Pharmaceutical Products

This article first appeared in World Trademark Review issue 62, published by Globe Business Media Group - IP Division. To view the issue in full, please go to

The question of parallel importation of pharmaceutical products has recently been considered by the Chancery Division of the UK's High Court in the case of Flynn Pharma Limited v Drugsrus Limited and Others. The decision provides a useful review of English law on parallel importation of pharmaceutical products. The decision of the High Court is currently under appeal and is listed to be heard in late February or early March 2017.

Flynn Pharma is a speciality pharmaceutical company that trades in both generic medicines and speciality brands. Its business model is to acquire marketing authorisations and to sell branded products once the patents on the products have expired - although generic versions of the products in question are usually competing in the market, there is still a demand for the branded product as they are often still prescribed by name by doctors. Flynn Pharma are generally responsible for the manufacture as well as the marketing and distribution of those products.

Drugsrus is a wholesaler of pharmaceutical products. The second defendant was a company that was set up to apply for and hold the product licences for parallel imports (PLPIs).

Flynn Pharma holds the UK marketing authorisation for a drug called phenytoin sodium, which is marketed in the UK as "Phenytoin Sodium Flynn". Flynn are therefore responsible for making sure that the regulatory requirements in relation to the quality of the manufacture of the product and the marketing of the product in the UK are met. In this case Flynn Pharma contracts out the manufacture of the product but remains responsible for the quality of the product.

Before September 2012, all phenytoin sodium supplied in the UK was made by Pfizer and sold under Pfizer's brand name EPANUTIN. Flynn Pharma and Pfizer entered into various agreements so that the marketing authorisations were assigned to Flynn Pharma in the UK, while Pfizer continued to market the product in some other Member States as EPANUTIN.

Drugsrus planned to import into the UK Epanutin which was being sold in other EU Member States, rebranded as "Phenytoin Sodium Flynn".

Flynn Pharma, the proprietor of a UK and an EU trade mark for the word FLYNN in class 5 for pharmaceutical products, objected to Drugsrus' plan to apply their trade mark, FLYNN, to the products they were going to be importing for sale on the UK market. Consequently they brought the infringement claim against Drugsrus asking the court to grant an injunction.

The UK prescription drug market

The High Court looked the UK prescription pharmaceutical market. The control of the price at which a prescription pharmaceutical product can be sold in the UK depends on whether the product is a branded or generic product. The price at which branded products can be sold to pharmacists is regulated by the pharmaceutical price regulation scheme (PPRS). The price of generic products (ie those sold under the drug's international non-proprietary name (INN)) are not regulated by the PPRS. Instead the price paid by the NHS is determined by what the pharmacies are charged for the products.

In the UK, most prescriptions are written by a doctor and are filled by retail pharmacists who buy their stock from wholesalers. Pharmacies receive the same payment for prescriptions they fulfil whether the generically written prescription is filled by a branded product or a generic product. They will obviously make more profit if they can supply a generic product. If the prescription written by the doctor refers to a specific branded product then the pharmacist must fill the prescription with the branded product. If the prescription refers to the product only by its generic name then the pharmacist can choose which product to use, the generic or the branded.

Parallel imports

Drugsrus initially imported the product under the brand name EPANUTIN, but due to the difference in price it could command for this product in the UK they looked about for an alternative. Drugsrus applied to vary their PLPI to permit the marketing of the imported product under the INN. The MHRA (the UK government medicines regulatory body) would not accept this. In the context of this type of drug, their guidance is that the name for the parallel import product should be the name under which the UK cross-referred product is marketed (Phenytoin Sodium Flynn) or the name of the product in the source country.

Using the name EPANUTIN was not attractive to Drugsrus because it would mean that pharmacists would not be able to use their product to fulfil prescriptions written for "Phenytoin Sodium Flynn" but only for prescriptions for Epanutin or phenytoin sodium. There was also an issue with guaranteeing a continuous supply of the drug by way of parallel importation. It would be less of an issue if the product was named Phenytoin Sodium Flynn which was available from other sources if the supply from Drugsrus was ever interrupted.

Trade mark use?

Turning to the questions of trade mark law to be addressed, firstly Drugsrus tried to argue that the use they were making of the FLYNN name was not "trade mark use". Drugsrus tried to rely on a defence under section 11(2)(b) of the 1994 Trade Marks Act arguing that the use of FLYNN was as a description of the goods not an indication of their origin. The court did not accept this. It was of the view that the mark FLYNN would be perceived by consumers as a mark of origin as they will interpret it as being an indication of the holder of the marketing authorisation and therefore the origin of the goods. This was the case even if there was a disclaimer printed on the packaging.

Rights exhausted?

The court then considered whether there was a defence to infringement on the basis that as a result of the relationship between Flynn and Pfizer, Flynn's rights to prevent the products being placed on the market in the UK under the FLYNN trade mark where exhausted. The court looked at whether the parallel imported goods must have placed in the market in the EU by the same entity that owns the trade mark in the UK.

After a detailed review of the case law, the court held that the entity needed to be the same. It said that it would not be right to say that the owner of the right in the importing Member State is, directly or indirectly, able to determine the products to which the trade mark may be affixed in the exporting Member State and to control their quality. It went on to hold that Flynn Pharma's trade mark rights in the name Phenytoin Sodium Flynn were not exhausted in respect of packages of Epanutin placed on the market in other Member States. Flynn Pharma was therefore entitled to prevent the relabelling of the parallel imported product by the Defendants.

Unlawful restriction on trade?

For the sake of completeness, the court then went on to consider the question of whether the use of trade mark law to prevent the parallel importation of these goods was contrary to EU law. The court reviewed the extensive jurisprudence on this issue including Bristol-Meyers Squibb v Paranova and then Pharmacia & Upjohn v Paranova. The court looked at the requirement that a trade mark owner may not enforce its mark against parallel imported goods which are re-branded if it is shown that it is necessary to re-brand in order to gain effective access to the market.

This was the main issue considered by the Court of Appeal in the Speciality European Pharma case. In that case, Mr Justice Floyd held that "the condition of necessity is satisfied if, in a specific case, the prohibition imposed on the importer against replacing the trade mark hinders effective access to the market of the importing member is saying that he must not be hindered from access to a substantial part of the market" (emphasis added).

Following Specialty European Pharma, the court held that Drugsrus had established that it was necessary for them to rebrand the Epanutin as Phenytoin Sodium Flynn. This was because of the data provided to the court showed that while 90 per cent of prescriptions were written generically about seven to nine per cent were written for Phenytoin Sodium Flynn. Where the branded product is named on the prescription the pharmacist can only supply the branded product. This meant that Drugsrus were excluded from the seven to nine per cent of the market where the branded product was named in the prescription and the court held that this share of the market could not be considered insignificant. On this basis the court held that it was necessary for the Epanutin to be rebranded as Phenytoin Sodium Flynn in order to gain access to the market.

While it is not surprising that the court held that this would be trade mark infringement given the lack of control Flynn Pharma would have had on the products going on the market under their trade mark it is always helpful to have further explanations of the key issues at stake by the court. The decision is interesting in the reasoning that being shut out of such a low percentage of the market was considered enough to make it necessary for the product to be rebranded. It will be interesting to see how this decision is treated by the Court of Appeal on appeal early next year.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.